Lupin#39;s Nilesh Gupta says new launches will help turn the corner in coming quarters

Lupin is hoping to turn the corner in the US, led by key approvals of generic versions of Renexa and Synthroid in place and a possible launch of Albuterol MDI in second half of FY20.

from Moneycontrol Business News https://ift.tt/2SDta7v